Boston Scientific Corporation $BSX Shares Acquired by Intech Investment Management LLC

Key Points

• Intech Investment Management LLC raised its stake in Boston Scientific Corporation by 0.9%, owning a total of 382,165 shares valued at approximately $38.6 million as of the latest reporting period.
• Insider trading activity includes Arthur C. Butcher selling 17,313 shares, reducing his position by 42.32%, while Yoshiaki Fujimori sold 2,901 shares, marking a 58.23% decrease in his holdings.
• Multiple analysts have upgraded Boston Scientific's stock ratings, with Wells Fargo and Oppenheimer increasing their price targets, indicating a consensus rating of "Buy" with a target of $117.79.

Intech Investment Management LLC increased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 382,165 shares of the medical equipment provider's stock after buying an additional 3,558 shares during the quarter. Intech Investment Management LLC's holdings in Boston Scientific were worth $38,553,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BSX. GAMMA Investing LLC lifted its position in Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after buying an additional 2,556,078 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Boston Scientific by 18.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after buying an additional 1,709,461 shares during the period. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after buying an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after buying an additional 1,664,108 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in Boston Scientific by 161.9% during the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after purchasing an additional 1,536,663 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BSX. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Leerink Partners began coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Thursday. Finally, UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Performance

Shares of BSX traded down $1.53 during trading hours on Monday, hitting $101.18. The stock had a trading volume of 3,581,921 shares, compared to its average volume of 7,466,002. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a 50-day moving average price of $104.86 and a 200 day moving average price of $102.27. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a market capitalization of $149.92 billion, a price-to-earnings ratio of 60.23, a PEG ratio of 2.47 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the business posted $0.62 EPS. The business's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.